纵隔淋巴结评估预测间质性肺疾病预后:观察性队列研究及独立验证
该观察性队列研究评估了胸部CT纵隔淋巴结(MLN)增大对间质性肺疾病(ILD)患者临床结局的预测价值。在1,094例ILD患者中,66%存在MLN增大(≥10 mm),其与无移植生存期(TFS)降低及全因和呼吸相关住院风险升高独立相关,并伴有肺功能下降和血浆可溶性CD40L水平降低。外部数据集独立分析验证了上述发现。
要点
- ILD患者胸部CT纵隔淋巴结增大(≥10 mm)与无移植生存期缩短及住院风险增加相关。
- MLN增大患者肺功能更低,血浆可溶性CD40L浓度降低。
- 血浆IL-10 >45 pg/ml预测死亡风险升高,MLN与细胞因子或可改善预后模型。
核心结论
- 纵隔淋巴结增大可预测ILD患者的无移植生存期和住院风险。
- 纵隔淋巴结增大与循环可溶性CD40L水平降低相关。
- 将纵隔淋巴结和细胞因子纳入现有预测模型可能改善ILD预后评估。
研究设计与样本
- 观察性队列研究,纳入10年间基线评估的ILD患者,排除结节病和药物毒性相关ILD。
- 共评估1,094例患者胸部CT(平均年龄64岁,52%男性),并在三个独立ILD队列中评估结局。
主要发现
- 纵隔淋巴结增大(≥10 mm)见于66%(n=726)的患者。
- 与MLN<10 mm者相比,MLN增大者无移植生存期风险比HR为1.53(95%CI 1.12-2.10,P=0.008)。
- MLN增大者全因住院发生率比IRR为1.52(95%CI 1.17-1.98,P=0.002),呼吸住院IRR为1.71(95%CI 1.15-2.53,P=0.008)。
- MLN增大者肺功能更低,血浆可溶性CD40L浓度为376 pg/ml vs. 505 pg/ml(P=0.001)。
- 血浆IL-10浓度>45 pg/ml预测死亡风险HR为4.21(95%CI 1.21-14.68,P=0.024)。
关键数值与推荐
- 纵隔淋巴结增大定义为直径≥10 mm。
- 血浆IL-10浓度>45 pg/ml作为预测死亡风险的阈值。
临床怎么用
- 在ILD患者基线胸部CT评估中应关注纵隔淋巴结大小,≥10 mm提示预后较差。
- 纵隔淋巴结增大患者需更密切监测肺功能、住院风险及无移植生存。
- 可考虑结合血浆可溶性CD40L和IL-10等细胞因子指标优化风险分层。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Mediastinal lymph node (MLN) enlargement on chest computed tomography (CT) is prevalent in patients with interstitial lung disease (ILD) and may reflect immunologic activation and subsequent cytokine-mediated immune cell trafficking. OBJECTIVES: We aimed to determine whether MLN enlargement on chest CT predicts clinical outcomes and circulating cytokine levels in ILD. METHODS: MLN measurements were obtained from chest CT scans of patients with ILD at baseline evaluation over a 10-year period. Patients with sarcoidosis and drug toxicity-related ILD were excluded. MLN diameter and location were assessed. Plasma cytokine levels were analyzed in a subset of patients. The primary outcome was transplant-free survival (TFS). Secondary outcomes included all-cause and respiratory hospitalizations, lung function, and plasma cytokine concentrations. Cox regression was used to assess mortality risk. Outcomes were assessed in three independent ILD cohorts. MEASUREMENTS AND MAIN RESULTS: Chest CT scans were assessed in 1,094 patients (mean age, 64 yr; 52% male). MLN enlargement (≥10 mm) was present in 66% (n = 726) and strongly predicted TFS (hazard ratio [HR], 1.53; 95% confidence interval [CI], 1.12-2.10; P = 0.008) and risk of all-cause and respiratory hospitalizations (internal rate of return [IRR], 1.52; 95% CI, 1.17-1.98; P = 0.002; and IRR, 1.71; 95% CI, 1.15-2.53; P = 0.008, respectively) when compared with subjects with MLN <10 mm. Patients with MLN enlargement had lower lung function and decreased plasma concentrations of soluble CD40L (376 pg/ml vs. 505 pg/ml, P = 0.001) compared with those without MLN enlargement. Plasma IL-10 concentration >45 pg/ml predicted mortality (HR, 4.21; 95% CI, 1.21-14.68; P = 0.024). Independent analysis of external datasets confirmed these findings. CONCLUSIONS: MLN enlargement predicts TFS and hospitalization risk in ILD and is associated with decreased levels of a key circulating cytokine, soluble CD40L. Incorporating MLN and cytokine findings into current prediction models might improve ILD prognostication.
引用
- Adegunsoye A, Oldham JM, Bonham C, et al. Prognosticating Outcomes in Interstitial Lung Disease by Mediastinal Lymph Node Assessment. An Observational Cohort Study with Independent Validation. Am J Respir Crit Care Med. 2019. PMID: 30216085. doi:10.1164/rccm.201804-0761OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。